...A. Worldwide sales were $21.4 billion for the third quarter of 2023, an increase of 6.8% versus the third quarter of 2022. B. Operational sales growth, which excludes the effect of translational currency, increased 6.4% as currency had a positive impact of 0.4 points. C. In the U.S., sales increased 11.1%. D. In regions outside the U.S., our reported growth was 1.6%. E. Operational sales growth outside the U.S. was 0.7%, with currency positively impacting our reported OUS results by 0.9 points. F. It is important to note that operational sales in Europe were negatively impacted by the COVID-19 vaccine and loss of exclusivity of ZYTIGA. G. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 4.9% worldwide, 8.9% in the U.S. and 0.3% outside the U.S. H. For the quarter, net earnings were $4.3 billion, and diluted earnings per share was $1.69 versus diluted earnings per share of $1.62 a year ago. I. Excluding after-tax intangible asset amortization...
